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Introduction
Airways of asthmatic patients are characterized by
damage of airway epithelium and profound infiltra-
tions of inflammatory cells including T cells,
eosinophils, basophils and monocytes [1]. Some fea-
tures of irreversible bronchial wall remodeling are also
present, even in those with mild asthma [1]. The irre-
versible changes in the airway wall consist of
increased deposition of extracellular matrix (ECM)
proteins, hyperplasia and hypertrophy of smooth mus-
cle cells, mucous cell metaplasia and increased num-
ber of blood vessels [1]. Progression of those changes
is associated with loss of lung function and increased
bronchial hyperreactivity [2]. Sensitization to house
dust mite allergens is an independent risk factor for
development of asthma [3]. In experimental studies
exposure to house dust mite allergens leads to chronic
airway inflammation with remodeling of airway wall
and subsequent progressive airflow limitation [4]. 
Urokinase-type plasminogen activator (uPA) and
plasminogen activator inhibitor-1 (PAI-1) play an
important role in regulation of the inflammatory
response and tissue remodeling [5,6]. In an animal
asthma model either suppression of PAI-1 expression
by knockout of the PAI-1 gene or delivery of exoge-
nous uPA leads to decreased airway remodeling and
decreased airway hyperresponsiveness [7-9]. In
humans, genetic variants of uPA and PAI-1 genes are
associated with increased risk of allergic asthma [10-
15]. In clinically stable, mild allergic asthma patients
elevated levels of uPA and PAI-1 in induced sputum
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have recently been demonstrated [16]. Moreover,
allergen exposure leads to elevation of plasma PAI-1
concentration in allergic asthma patients [17]. It is not
known wheather allergen exposure leads also to local
(intrabronchial) upregulation of PAI-1 expression pro-
moting in this way airway remodeling. 
It was therefore of interest to evaluate the changes
of uPA and PAI-1 in the airways of house dust mite
allergic asthmatics (HDM-AAs) in response to aller-
gen exposure.    
Methods
Thirty HDM-AAs, eight house dust mite allergic nonasthmatic
patients (HDM-ANAs) and ten nonactopic, healthy persons (HCs)
were recruited for the study. The allergic asthmatic patients had
recent episodes of dyspnea, cough and wheezing upon house dust
exposure and had positive skin prick test results with house dust
mite allergens, significant bronchoconstrictive response to inhaled
histamine and positive bronchial allergen challenge. All patients
who had received allergen immunotherapy or any antiasthma med-
ication, (with the exception of short-acting beta-agonists used as
needed) before the initial visit were not included in the study. The
short acting beta agonists were withdrawn at least 2 days before the
study. Other exclusion criteria included respiratory tract infection
within 3 months before the study, smoking, or any systemic dis-
ease. In 24 HDM-AAs allergen bronchial challenge with Der-
matophagoides pteronyssinus (Dp) extract, while in 6 HDM-AAs
sham bronchial challenge with saline were performed.
Skin prick tests. All persons were skin tested using prick method-
ology with a screening panel of aeroallergens (Allergopharma,
Reinbek, Germany) as described earlier [18].
Bronchial challenge. Histamine bronchial challenge was per-
formed according to the method previously described elsewhere
starting from a concentration of 0.62 mg/ml [18].  The procedure
was continued until either at least 20 % fall of FEV1 or histamine
concentration 32 mg/ml was reached. Bronchial reactivity to hista-
mine is expressed as histamine concentration causing 20% fall of
FEV1 (PC20). 
Bronchial provocation test with aqueous Dp extracts (Aller-
gopharma, Germany) was performed according to the method previ-
ously described elsewhere [18]. In brief, patients inhaled five-fold
increasing doses of allergen starting from a dose 0.8 SBE. Allergen
inhalations were continued until either at least 20% fall of FEV1 or
a cumulative dose 5000 SBE was reached. Then FEV1 was measured
every 15 minutes during the first hour, every 60 minutes during the
next 11 hours and after 24 hours. Bronchial reactivity to Dp is
expressed as Dp dose causing 20% fall of FEV1 (PD20). 
Bronchial challenge with histamine or Dp allergen extract were
performed only in HDM-AAs.  
Exhaled nitric oxide measurements. Fractional exhaled nitric
oxide (FeNO) concentration was evaluated "on-line" using 
a chemiluminescence analyzer NOATM 280i (Sievers, USA). The
measurements were performed according to the ATS recommenda-
tions as described before [19]. Briefly, each patient exhaled against
the fixed expiratory resistance of 16 cm H20, which resulted in 
a constant flow of 50 mL/s. Both NO concentration and flow rate
were displayed on the screen. A plateau of NO concentration in the
exhaled air at the selected exhalation rate was automatically select-
ed by the computer software according to the ATS recommenda-
tions. The NO measurements were repeated 3 times and the mean
value was used for analysis. 
Sputum induction. Sputum was induced as described before [16].
Briefly, after premedication with 200 mcg of salbutamol patients
inhaled hypertonic saline solution (3 to 5% NaCl). The collected
sputum volume was measured, mixed with an equal volume of
0.1% DTT (dithiotreitol) and than rocked at room temperature for
15 minutes. The samples were subsequently filtered through 
0.42-μm Millipore filter and centrifuged at 1500 g for 10 minutes.
The supernatants were immediately aliquoted and frozen at -70°C
until further analysis. The pellets were resuspended in phosphate-
buffered saline and total number of nonsquamous cells was
assessed using Fuchs Rosenthal chamber. Sputum was induced 24
hours before allergen challenge (T0) and 24 hours after allergen
challenge (T24). 
Biochemical and immunologic assays. Sputum PAI-1 and uPA
concentrations were evaluated using enzyme-linked immunosor-
bent assays (Asserachrom, Diagnostica Stago, USA) according to
the manufacturer's instruction as described before [16]. All sam-
ples were run in duplicates. Serum concentration of total IgE (tIgE)
and allergen specific IgE (DpIgE) were evaluated using UnicCap
(Phadia, Sweden). 
Ethical issues. The study was approved by the local Ethics Com-
mittee (R-I-003/188/2005). All participants provided written
informed consent.   
Statistical analysis. Continuous variables were compared using
the Student t-test. Fisher exact test was used to compare discrete
parameters. Multiple regression analysis was used to determine
relationship between quantitative parameters. Data for continuous
variables were expressed as means with standard deviations. All
computations were carried out using the Statistica software. 
Results
There was no significant difference in gender distribu-
tion and age between HDM-AAs, HDM-ANAs and HC
(Table 1). Patients with asthma were characterized by
significantly lower lung function parameters and signif-
icantly elevated FeNO (Table 1). At T0, in HDM-AAs
the mean sputum concentrations of uPA (157±96 pg/ml)
and PAI-1 (4398±1212 pg/ml) were significantly greater
than in HCs (23.8±6.7 pg/ml; p<0.0001 and 566±189
pg/ml; p<0.0001, for uPA and PAI-1 respectively)
(Table 1). In HDM-ANAs, at T0, the mean concentra-
tion of uPA (34.8±22.5 pg/ml) and PAI-1 (821±387
pg/ml) were significantly lower than in HDM-AAs
(p=0.002 and p<0.0001; for uPA and PAI-1 respective-
ly). When HDM-AAs were stratified according to the
type of asthmatic response to allergen challenge into
those who responded with isolated early response (sin-
gle responders – SRs) and those who responded with
both early and late asthmatic responses (dual responders
– DRs) no significant differences in the baseline lung
function parameters eNO concentration, sputum cell
counts, or sputum uPA and PAI-1 concentrations were
demonstrated between SRs and DRs (Table 1). No sig-
nificant difference in baseline uPA or PAI-1 sputum
concentrations between the HDM-AAs subgroup chal-
lenged with Dp and that challenged with saline was
demonstrated (Fig. 1). 
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At T24 increase in sputum PAI-1 concentration was
seen in all (100%) HDM-AAs challenged with Dp aller-
gen, but only in 2 out of 6 (33.3%) sham challenged
HDM-AAs (p=0.0006) and in 4 out of 8 (50%) Dp chal-
lenged HDM-ANAs (p=0.002 vs HDM-AAs). Sputum
uPA increased in 16 out of 24 (66.7%) HDM-AAs chal-
lenged with Dp, in 2 out of 6 (33.3%) sham challenged
HDM-AAs (p=0.184) and in 4 out of 8 (50%) Dp chal-
lenged HDM-ANAs (p=0.43 vs HDM-AAs). In HDM-
AAs challenged with Dp significant increase in the
mean sputum PAI-1 from 4342±1263 pg/ml at T0 to
6252±2324 pg/ml at T24 (p<0.0001) was observed. Nei-
ther in sham challenged HDM-AAs (4616±1071 pg/ml
at T0 and 4571±837 pg/ml at T24; p=0.759) nor in
HDM-ANAs challenged with Dp (34.8±22.5 pg/ml at
T0 and 40.5±28.5 pg/ml at T24; p=0.65) significant
change in the mean sputum PAI-1 concentration after
the allergen challenge was demonstrated. In Dp chal-
lenged HDM-AAs significant increase in the mean spu-
tum uPA concentration from 151±96 pg/ml at T0 to
187±144 pg/ml at T24 (p=0.033) was seen but neither in
sham challenged HDM-AAs (179±99 pg/ml at T0 and
168±87 pg/ml at T24; p=0.152) nor in Dp challenged
HDM-ANAs (821±387 pg/ml at T0 and 875±406 pg/ml
at T24; p=0.79) significant difference in mean sputum
uPA concentration was demonstrated. Among HDM-
AAs significant increase in PAI-1 concentration was
seen in both SR (6143±2151 pg/ml at T24; p=0.007) and
in DR (6336±2532 pg/ml at T24; p=0.0003), but signifi-
cant increase in uPA concentration was seen only in DR
(244±161 pg/ml at T24; p=0.01) but not in SR (135±103
pg/ml at T24; p=0.3) . After the challenge the mean
uPA/PAI-1 ratio decreased significantly in Dp chal-
lenged HDM-AAs, but did not change significantly in
those challenged with saline (Fig. 2). The changes of
sputum PAI-1 concentration after allergen challenge
significantly, inversely correlated with baseline FEV1
and logPC20 (r=-0.636; p=0.0008 and r=-0.878;
p<0.0001 respectively) (Fig. 3.). The changes of uPA
concentration after the challenge did not correlate with
FEV1 or logPC20 but correlated with the change in spu-
tum total cell count number (r=0.627; p=0.0014) and
with percentage of eosinophils in induced sputum
(r=0.645; p=0.0009) (not shown). 
Discussion
This study supports previous observations linking the
plasmin system with pathogenesis of allergic asthma [8-
16]. In the present study we demonstrate that, in the air-
ways of allergic asthma patients, allergen exposure
leads to up-regulation of both components of the plas-
min system: PAI-1 and uPA. Moreover, 24 hours after
the challenge, which corresponded to the time point
when resolution mechanisms are already in progress,
increase in sputum PAI-1 concentration considerably
exceeded that of uPA. This also holds true when the
molar concentrations of PAI-1 and uPA are compared.
Since the stoichiometry of PAI-1 and uPA in the PAI-1-
uPA inactive complex is 1:1, it can be assumed that at
T24 the inhibitory potential of PAI-1 exceeds the prote-
olytic activity of uPA. Interestingly, in individual
patients, the increase of PAI-1 concentration 24 hours
after allergen challenge was greater than the total uPA
concentration at that time point suggesting that even the
newly generated PAI-1 can potentially neutralized the
whole uPA activity in the sputum at T24. Increasing
body of evidence indicates that the predominance of
PAI-1 inhibitory effects promotes irreversible tissue
remodeling. In mice overexpressing PAI-1, intratracheal
administration of bleomycin resulted in increased fibro-
sis [20]. On the contrary, pulmonary fibrosis in response
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Table 1. Patients characteristics 
to bleomycin is significantly attenuated in PAI-1 knock-
out mice. Similarly, in PAI-1 deficient mice sensitized to
ovalbumin (OVA) attenuation of extracellular matrix
deposition in response to OVA inhalation was demon-
strated [8].  The association between Dp induced upreg-
ulation of PAI-1 in the airways and airway remodeling
is further supported by highly significant correlations
between the allergen induced changes in sputum PAI-1
concentration and baseline FEV1 or bronchial reactivity.
This may, at least partially, explain why repeated expo-
sure to dust mite allergens in sensitized patients may
lead to increased bronchial hyperreactivity. Unfortu-
nately we are not able to reveal mechanisms leading to
greater upregulation of PAI-1 expression in some of the
studied patients. Association between genetic predispo-
sition to greater PAI-1 synthesis and asthma or
bronchial reactivity demonstrated in the previous stud-
ies indicates that genetic factor(s) may be involved in
this processes.  
Allergen exposure is associated with increased
plasma PAI-1 concentration [17]. Plasma exudate from
microvascular leakage during asthmatic response may
lead to efflux of PAI-1 into airways. However, it seems
that plasma is not the predominant source of sputum
PAI-1 because elevated sputum levels of PAI-1 are still
observed 24 hours after the challenge, while at that
time point plasma levels within the circulation return
to baseline values [17]. Synthesis of both PAI-1 and
uPA is rapidly induced by many factors including
cytokines, growth factors and hormones [5,6]. Several
potential sources of PAI-1 and uPA in the airways of
asthmatic patients have to be considered. The main
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Fig. 1 a and b Sputum PAI-1 and uPA concentration before (T0)
and after (T24) allergen challenge. * – significantly greater in com-
parison with T0.
Fig. 2 a and b. Changes in the ratio uPA/PAI-1 concentration in
induced sputum before and after Dp challenge (a) and sham chal-
lenge (b).
cells responsible for production of plasminogen acti-
vators are endothelial cells, fibroblasts, mast cells,
monocytes/macrophages, smooth muscle cells and
epithelial cells, while plasmin system inhibitors are
synthesized by endothelium, platelets and megakary-
ocytes, neutrophils, monocyte/macrophages,
eosinophils, smooth muscle cells, fibroblasts and
epithelial cells [5,21,22]. Interestingly, activated mast
cells can secrete PAI-1, while activated T cells synthe-
size uPA [23,24]. Bronchial epithelial cells, which
make up an interface between outer and inner environ-
ments, have been shown to release both PAI-1 and uPA
[25,26]. Several exogenous and endogenous factors
induce PAI-1 and uPA synthesis by bronchial epithelial
cells [25-27]. Even mechanical stimulation induces
expression of all components of the plasmin system in
cultured bronchial epithelial cells [27]. Similarly, in
ovalbumin sensitized mice allergen exposure leads to
enhanced PAI-1 expression in bronchial epithelial cells
[22] Moreover, human bronchial epithelial cells can be
activated by enzymatically active and non-enzymatic
house dust mite allergens.  
In an animal asthma model chronic allergen exposure
is associated with airway remodeling and bronchial
hyperreactivity [22]. Some features of airway remodel-
ing were seen long after cessation of allergen exposure,
which indicates that in sensitized animals prolonged
allergen exposure may lead to chronic asthma pheno-
type. Intratracheal administration of exogenous uPA in
OVA sensitized and exposed to OVA mice leads to ame-
lioration of airway remodeling and airway hyperrespon-
siveness [9]. In humans, genetic predisposition for aug-
mented PAI-1 synthesis, caused by the presence of 
4G allele in the position -675 of the PAI-1 gene, is 
associated with enhanced bronchial reactivity and
decreased lung function [11-15]. Elevated levels of 
PAI-1 in sputum of asthmatic patients has also been
reported [16,28]. The exact role of genetic predisposition
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Fig. 3 a-d. Correlations between the change in sputum PAI-1 (a and c) or uPA (b and d) concentrations and baseline bronchial reactivity
expressed as logPC20 (a and b) or baseline FEV1 (c and d). 
and environmental factors in activation of the plasmin
system in the airways has to be determined. 
In summary, our study demonstrates that in Dp
sensitized asthmatic patients allergen exposure leads
to local activation of the plasmin system in the air-
ways, with predominant anti-proteolytic effects deliv-
ered by overwhelming increase of PAI-1 release. Fur-
ther studies are warranted to determine mechanisms
which lead to activation of plasmin system in
response to allergen exposure.  
Acknowledgments: This work was supported by a grant from Med-
ical University of Bialystok research grants 3-35493 (KK and AB-L) 
References
[ 1] Busse W, Elias J, Sheppard D, Banks-Schelegel A. Airway
remodeling and repair. Am J Respir Crit Care Med.
1999;160:1035-42.
[ 2] Chetta A, Foresi A, Del Donno M, Bertorelli G, Pesci A,
Olivieri D. Airway remodeling is a distinctive feature of asth-
ma and is related to severity of asthma. Chest. 1997;111:852-7.
[ 3] Global Strategy for Asthma Management and Prevention.
NIH publication No 02-365P. Revised 2002.
[ 4] Johnson JR, Wiley RE, Fattouh R et al. Continuous exposure
to house dust mite elicits chronic airway inflammation and
structural remodeling. Am J Respir Crit Care Med.
2004;169:378-85.
[ 5] Kucharewicz I, Kowal K, Buczko W, Bodzenta-Lukaszyk A.
The plasmin system in airway remodeling. Thromb Res.
2003;112:1-7. 
[ 6] Ma Z, Paek D, Oh CK. Plasminogen activator inhibitor-1 and
asthma: role in the pathogenesis and molecular regulation.
Clin Exp Allergy. 2009;39:1136-44.
[ 7] Sejima T, Madoiwa S, Mimuro J, Sugo T, Okada K, Ueshima
S et al. Protection of plasminogen activator inhibitor-1-defi-
cient mice from nasal allergy. J Immunol. 2005;174:8135-43. 
[ 8] Oh CK, Ariue B, Alban RF, Shaw B, Cho SH. PAI-1 promotes
extracellular matrix deposition in the airways of a murine
asthma model. Biochem Biophys Res Commun.
2002;294:1155-60. 
[ 9] Kuramoto E, Nishiuma T, Kobayashi K, Yamamoto M, Kono
Y, Funada Y, Kotani Y et al. Inhalation of urokinase-type
plasminogen activator reduces airway remodeling in a murine
asthma model. Am J Physiol Lung Cell Mol Physiol.
2009;296:L337-46.
[10] Begin P, Tremblay K, Daley D, Lamire M, Claveau S et al.
Association of urokinase-type plasminogen activator with
asthma and atopy. Am J Respr Crit Care Med.
2007;175:1109-16. 
[11] Cho SH, Hall IP, Wheatley A, Dewar J, Abraha D, Del Mundo
J et al. Possible role of the 4G/5G polymorphism of the plas-
minogen activator inhibitor 1 gene in the development of
asthma. J Allergy Clin Immunol. 2001;108:212-14. 
[12] Buckova D, Izakovicova Holla L, Vacha J. Polymorphism
4G/5G in the Plasminogen activator inhibitor-1 (PAI-1) gene
is associated with IgE-mediated allergic diseases and asthma
in the Czech population. Allergy. 2002;57:446-8. 
[13] Pampuch A. Kowal K, Bodzenta-Lukaszyk A, Di Castelnuo-
vo A, Chyczewski L, Donati MB, Iacoviello L. The -675
4G/5G plasminogen activator inhibitor-1 promoter polymor-
phism in house dust mite-sensitive allergic asthma patients.
Allergy. 2006;61:234-8. 
[14] Kowal K, Bodzenta-Lukaszyk A, Pampuch A, Szmitkowski
M, Zukowski S, Donati MB, Iacoviello L. Analysis of -675
4G/5G SERPINE1 and C-159T CD14 polymorphisms in
house dust mite-allergic asthma patients. J Investig Allergol
Clin Immunol. 2008;18:284-92.
[15] Ozbek OY, Atac FB, Ogus E, Ozbek N. Plasminogen activa-
tor inhibitor-1 gene 4G/5G polymorphism in Turkish children
with asthma and allergic rhinitis. Allergy Asthma Proc.
2009;30:41-6. 
[16] Kowal K, Zukowski S, Moniuszko M, Bodzenta-Lukaszyk A.
Plasminogen activator inhibitor-1 (PAI-1) and urokinase plas-
minogen activator (uPA) in sputum of allergic asthma
patients. Folia Histochem Cytobiol. 2008;46:193-8.
[17] Kowal K, Bodzenta-Lukaszyk A, Pampuch A, Szmitkowski
M, Donati MB, Iacoviello L. Plasminogen activator inhibitor-
1 (PAI-1) plasma concentration in allergic asthma patients
during allergen challenge. Int Arch Allergy Immunol.
2007;144:240-6.
[18] Kowal K, Osada J, Zukowski S, Dabrowska M, DuBuske
LM, Bodzenta-Lukaszyk A. Expression of interleukin-4
receptor in bronchial asthma patients treated with specific
immunotherapy (SIT). Ann Allergy Asthma Immunol.
2004;93:68-75.
[19] Kowal K, Moller HJ, DuBuske LM, Moestrup SK, Bodzenta-
Lukaszyk A. Differential expression of monocyte CD163 in
single- and dual-asthmatic responders during allergen-
induced bronchoconstriction. Clin Exp Allergy.
2006;36:1584-91. 
[20] Eitzman DT, McCoy RD, Zheng X, Fay WP, Shen T, Gins-
burg D, Simon RH. Bleomycin-induced pulmonary fibrosis in
transgenic mice that either lack or overexpress the murine
plasminogen activator inhibitor-1 gene. J Clin Invest.
1996;97:232-7.
[21] Kucharewicz I, Mogielnicki A, Kasacka I, Buczko W,
Bodzenta-Lukaszyk A. Plasmin system regulation in an oval-
bumin-induced rat model of asthma. Int Arch Allergy
Immunol. 2008;147:190-6. 
[22] Kelly MM, Leigh R, Bonniaud P, Ellis R, Wattie J, Smith MJ
et al. Epithelial expression of profibrotic mediators in a model
of allergen-induced airway remodeling. Am J Respir Cell Mol
Biol. 2005;32:99-107. 
[23] Cho SH, Tam SW, Demissie-Sanders S, Filler SA, Oh CK.
Production of plasminogen activator inhibitor-1 by human
mast cells and its possible role in asthma. J Immunol.
2000;165:3154-61. 
[24] Gunderson D, Tran-Thang C, Sordat B, Mourali F, Ruegg C.
Plasmin induced proteolysis of tenascin-C: modulation by T
lymphocyte-derived urokinase-type plasminogen activator
and effect on T lymphocyte adhesion, activation, and cell
clustering. J Immunol. 1997;158:1051-60.
[25] Shetty S, Bdeir K, Cines DB, Idell S. Induction of plasmino-
gen activator inhibitor-1 by urokinase in lung epithelial cells.
J Biol Chem. 2003;278:18124-31.  
[26] Marshall BC, Xu QP, Rao NV, Brown BR, Hoidal JR. Pul-
monary epithelial cell urokinase-type plasminogen activator.
Induction by interleukin-1β and tumor necrosis factor-α.
[27] Chu EK, Cheng J, Foley JS, Mecham BH, Owen CA, Haley
KJ, et al. Induction of the plasminogen activator system by
mechanical stimulation of human bronchial epithelial cells.
Am J Respir Cell Mol Biol. 2006;35:628-38.
[28] Ciao W, Hsu YP, Ishizaka A, Kirikae, Moss RB. Sputum
cathelicidin, urokinase plasminogen system components and
cytokine discriminate cystic fibrosis, COPD and asthma
inflammation. Chest. 2005;128:2316-26.
Submitted: 16 August, 2010
Accepted after reviews: 8 September, 2010
523PAI-1 and uPA in sputum after allergen challenge
©Polish Histochemical et Cytochemical Society
Folia Histochem Cytobiol. 2010:48(4): 523 (518-523) 
10.2478/v10042-010-0075-2
